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Abstract
Purpose This retrospective study evaluated the effectiveness
and tolerability in clinical practice of an L-proline–stabilized
10 % intravenous immunoglobulin (IVIG; Privigen®) in pa-
tients with primary (PID) or secondary immunodeficiency
(SID).
Methods Patients from 6 centers in Europe and the US
were treated with individually determined regimens of
Privigen® for ≥3 months. Serum immunoglobulin G
(IgG) trough levels, annualized rates of infection, hos-
pitalization and antibiotics use, and the incidence of
adverse events (AEs) were analyzed.
Results Of 72 patients, three infants with severe com-
bined immunodeficiency (SCID) were analyzed sepa-
rately. The remaining 69 patients (52.2 % male; median
age 38 years [range: 0.1–90.0]) with PID (82.6 %) or
SID (17.4 %) received a mean (±standard deviation)
Privigen® dose of 532±250 mg/kg/month resulting in
trough serum IgG levels of 407–1,581 mg/dL (median:
954 mg/dL). Ten patients (14.5 %) experienced 11 seri-
ous bacterial infections over 22.0±15.0 months of treat-
ment (0.087 events/patient/year, upper one-sided 99 %
confidence interval: 0.170), the most common being
pneumonia (11.6 %). The rates for any infection and
hospitalization were 1.082 events/patient/year and
3.63 days/patient/year, respectively. Two patients with
severe disease accounted for 303 of 460 hospital days.
Across all 72 patients, 13 (18.1 %) patients experienced
AEs, including 10 (13.9 %) patients with AEs at least
possibly related to Privigen®, including headache
(8.3 %), fever, and chills (2.8 % each). No related
serious AEs were reported. One infant with SCID died
due to severe viral infection.
Conclusions Despite the heterogeneous population, effective-
ness and tolerability of Privigen® in clinical practice closely
matched those reported in clinical studies.
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Introduction
Immunoglobulin G (IgG) replacement therapy, administered
either intravenously (IVIG) or subcutaneously (SCIG), is the
standard of care for patients with primary (PID) and secondary
immunodeficiencies (SID). IVIG, and in some cases SCIG,
are also used for the treatment of autoimmune conditions,
such as immune thrombocytopenia, chronic inflammatory
demyelinating polyneuropathy, Guillain–Barré syndrome
and Kawasaki disease [1–5].
Privigen® (IgPro10; CSL Behring, Berne, Switzerland) is a
10 % liquid preparation of polyclonal human IgG for intrave-
nous administration, stabilized with L-proline [6]. Privigen® is
indicated as replacement therapy for PID including, but not
limited to, congenital agammaglobulinemia, common variable
immunodeficiency (CVID), X-linked agammaglobulinemia
(XLA), Wiskott-Aldrich syndrome (WAS), and severe com-
bined immunodeficiencies (SCID) [7]. In the EU, Privigen® is
also indicated for the IgG replacement therapy in some patients
with SID. Clinical studies have demonstrated the efficacy and
tolerability of Privigen® in both adults and children with PID
[8–10]. In clinical studies, administration of Privigen® every 3
or 4 weeks helped decrease the risk of recurrent infections and
resulted in low annualized rates of serious bacterial infections
(SBIs), any infections, hospitalization and days missed from
school/work [8, 9]. Privigen® is well tolerated at infusion rates
up to 8 mg/kg/min (4.8 mL/kg/h), with many patients tolerating
infusion rates up to 12 mg/kg/min (7.2 mL/kg/h) [8–10].
Privigen® has been used in clinical practice since its registration
in 2009 leading to accumulation of sufficient real-life effective-
ness and safety data.
Registration studies of IVIG products are usually conduct-
ed in relatively homogenous, carefully selected patient popu-
lations with well-defined forms of PID receiving standardized
treatment [8–12]. Here we report the real-life effectiveness
and tolerability of Privigen® in clinical practice in 6 clinics
located in Europe and in the United States (US). This retro-
spective cohort analysis (chart review) included patients with
a wide variety of PID and SID diagnoses, treated according to
local practice. Detailed data were obtained for most of the
patients, with exceptions as noted in the text.
Methods
Patients and Data Collection
Patients of all ages who have received Privigen® for the
treatment of PID or SID for at least 3 months in clinical
practices in Europe and the US were eligible for this study.
The Privigen® treatment schedule and doses were determined
individually at the discretion of the investigators and accord-
ing to the patients’ conditions and local practices. Information
about dosage and regimens of Privigen® and other IgG prod-
ucts was collected retrospectively using a predefined data
collection template. This study was conducted in accordance
with the International Conference on Harmonisation Good
Clinical Practice guidelines, and the Declaration of Helsinki
(2008 version). The protocol of the study and all other study
documents were approved by the relevant independent Ethics
Committees or Institutional Review Boards.
Effectiveness and Tolerability Assessments
Infant patients with severe combined immunodeficiency
(SCID) were excluded from the main analysis and analyzed
separately, due to potential lack of cell-mediated immunity
leading to extremely severe phenotypes (see also Results and
Discussion). In the remaining patients, demographics and the
effectiveness of Privigen® were analyzed for patient sub-
groups based on age at the start of Privigen® (age classes):
infants (0–2 years old [y. o.]), children and adolescents (3–
15 y. o.), adults (16–64 y. o.), and elderly patients (>64 y. o.).
The most recent available trough serum IgG levels
achieved on Privigen® were collected and, if applicable, com-
pared with the IgG levels achieved on previous IgG treatment.
SBIs were defined according to the diagnostic criteria of the
US Food and Drug Administration (FDA) [13]; other infec-
tions were defined at the discretion of the investigators. An-
nualized rates per patient were calculated for SBIs, other
infections, any infection, days spent in hospital, days missed
from performing normal daily activities due to infection, and
days on antibiotics for prophylaxis or treatment of infection.
Days spent in hospital by retired or unemployed adult patients
were considered as missed from performing normal daily
activities. Data of one patient hospitalized during Privigen®
treatment due to severe thrombocytopenia and of another
patient hospitalized without a report of infection were includ-
ed in the calculation of the relevant annualized rates to reflect
the real-life characteristics of patients.
Tolerability of Privigen® was analyzed in all patients, in-
cluding the infant patients with SCID. Privigen® infusion rate
in each patient was calculated by dividing a single Privigen®
dose by the entire duration of infusion. Percentages of patients
who experienced at least one adverse event (AE) or serious AE
(SAE), categorized by relatedness to Privigen®, were calculat-
ed. AE and SAE rates per infusion were not calculated due to
missing data (exact number of events for each patient).
Statistical Methods
All data were analyzed by descriptive statistics, including the
mean, standard deviation (SD), median and range. Patients
with missing data were excluded from the corresponding
analyses, but included in other analyses, for which the data
were available.
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Annualized rates were calculated per patient per year
(365 days), based on the total exposure to Privigen® of the
patients included in each analysis. The annualized rate of SBIs
was calculated along with its upper one-sided 99 % confi-
dence interval (CI). Two-sided 95 % CIs were calculated for
annualized rates of other infections and any infection. All CIs
were calculated by the method described by Ulm et al. [14].
Correlation between the change in monthly IgG dose and the
change in IgG levels was analyzed by linear regression.
Results
Patients
A total of 72 patient records were collected at 6 sites in Europe
and the US. Three records of infants with SCIDwere analyzed
separately (except for tolerability; see also Discussion). These
included two boys and one girl with the median age of
3 months at the start of Privigen® treatment.
The remaining 69 patients included both male and female
patients (Table I). The age at start of Privigen® treatment
ranged from 0.1 years (1.3 months) to 90.0 years, with a
median age of 38.0 years. The study included 23 (33.3 %)
pediatric patients who were under 16 y. o. at the start of
Privigen® treatment. Patients with either PID (n=57;
82.6 %) or SID secondary to cancer were included. The most
common diagnoses at the start of Privigen® treatment were
IgG subclass deficiency (n=18; 26.1 %; diagnosis by the
referring physician), XLA (n=13; 18.8 %), CVID (n=10;
14.5 %), and chronic lymphocytic leukemia (CLL; n=8;
11.6 %). Fourteen patients with IgG subclass deficiency also
had specific antibody deficiency, i.e., poor response to Strep-
tococcus pneumoniae vaccine and recurrent infections despite
optimal therapy. Patients with XLA were present in all age
groups except for the elderly. Patients with CVID or IgG
subclass deficiency were observed mainly in the adult and
elderly age classes. SID was observed in adult and elderly
patients only.
Three non-infant patients with SCID underwent hema-
topoietic stem cell transplantation (HSCT) at least 6 months
before the end of the Privigen® treatment. Two adult
patients with SID received allogeneic bone marrow trans-
plantation, one before and one during the Privigen®
treatment.





Adults (16–64 y. o.) Elderly (>64 y. o.)
Number of patients, n (%) 69 (100.0) 6 (8.7) 17 (24.6) 32 (46.4) 14 (20.3)
Male gender, n (% of the age group) 36 (52.2) 5 (83.3) 11 (64.7) 13 (40.6) 7 (50.0)
Age [years] at start of Privigen®, median
(range)
38.0 (0.1–90.0) 1.5 (0.1–2.0) 9.0 (3.0–15.0) 52.0 (16.0–64.0) 71.5 (65.0–90.0)
Body weight [kg] at start of Privigen®,
median (range)
65.9 (5.6–122.8) 8.9 (5.6–11.5) 28.0 (11.5–90.1) 73.5 (40.0–122.0) 83.2 (36.0–122.8)
Diagnosis, n (%)
Any PID 57 (82.6) 6 (8.7) 17 (24.6) 26 (37.7) 8 (11.6)
IgG subclass deficiency 18 (26.1) 0 – 1 (1.4) 10 (14.5) 7 (10.1)
XLA 13 (18.8) 3 (4.3) 5 (7.3) 5 (7.3) 0 –
CVID 10 (14.5) 0 – 4 (5.8) 6 (8.7) 0 –
Hypogammaglobulinemia 6 (8.7) 0 – 1 (1.4) 4 (5.8) 1 (1.4)
SCID 3 (4.3) n/aa – 3 (4.3) 0 – 0 –
Otherb 7 (10.1) 3 (4.3) 3 (4.3) 1 (1.4) 0 –
Any SID 12 (17.4) 0 – 0 – 6 (8.7) 6 (8.7)
CLL 8 (11.6) 0 – 0 – 3 (4.3) 5 (7.3)
MM 2 (2.9) 0 – 0 – 1 (1.4) 1 (1.4)
FL 1 (1.4) 0 – 0 – 1 (1.4) 0 –
ALL 1 (1.4) 0 – 0 – 1 (1.4) 0 –
ALL acute lymphoblastic leukemia, CLL chronic lymphocytic leukemia, CVID common variable immunodeficiency, FL follicular lymphoma, IgE
immunoglobulin E, IgG immunoglobulin G, MM multiple myeloma, n number of patients, n/a not applicable, PID primary immunodeficiency, SCID
severe combined immunodeficiency, SID secondary immunodeficiency, XLA X-linked agammaglobulinemia, y. o. years old
a Infants with SCID (n=3) were analyzed separately (Table IV)
b Unspecified immunodeficiency, unspecified immune disorder, Wiskott-Aldrich syndrome, profound combined immunodeficiency, GATA-2 deficien-
cy or hyper-IgE syndrome, each in <3 (<4.3 %) patients
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IgG treatment
All patients received individual Privigen® doses of 196–
1,000 mg/kg per dosing cycle. All but two patients (n=67;
97.1 %) were treated with Privigen® every 3 or 4 weeks. An
adolescent patient with CVID and an adult patient with un-
specified hypogammaglobulinemia received Privigen® bi-
weekly at 555 mg/kg and 1,000 mg/kg, respectively. Both
these patients were hospitalized for extended periods of time
indicating a severe form of disease. Themean±SD duration of
Privigen® treatment for the entire cohort at the time of the
chart review was 22.0±15.0 months (median: 18.0 months,
range: 3–60months). This suggests that themajority of patients
were at steady-state Privigen dosing at the time of collecting
data for this report. The mean±SD monthly Privigen® dose in
all patients was 532±250 mg/kg/month (Table II). Mean
monthly doses were similar across all age groups, with the
lowest mean dose in infants (481 mg/kg/month) and the
highest mean dose in children and adolescents (606 mg/kg/
month).
Thirty-five (50.7 %) patients had been treated with other
IgG products before switching to Privigen®. The change in
the mean monthly IgG dose upon switching to Privigen® was
not statistically significant (536±320 mg/kg/month on
Privigen® vs. 483±204 mg/kg/month on previous IgG prod-
ucts; p=0.4; n=34). One patient with severe disease had an
increase in IgG dose of 1,154 mg/kg/month, which strongly
influenced the mean. Reported reasons of switching from
other IVIG products to Privigen® included change in insur-
ance coverage or product availability (n=6), systemic reac-
tions (n=2), smaller volume and shorter administration times
(n=1), and frequent infection with the previous IVIG products
(n=1). Eight (11.6 %) patients switched to Privigen® from
SCIG due to local reactions (n=3), change in insurance cov-
erage (n=2), systemic reactions (n=1) or difficulties with
home-based infusions in pediatric patients (n=1). Monthly
IgG doses were the same on Privigen® as on previous SCIG
(545±254 mg/kg/month vs. 542±244 mg/kg/month on previ-
ous SCIG). At the end of the observation period, 8 (11.6 %)
patients switched from Privigen® to SCIG and 1 patient
switched to a combination of Privigen® and SCIG.
The mean±SD duration of the entire Privigen® infusion,
including initial slow rates and a ramp-up, was 212±59 min
(median: 210 min, range: 90–392 min; n=66), resulting in the
median average infusion rate of 1.32 mL/kg/h (range: 0.73–
3.64 mL/kg/h). The median infusion rates in pediatric patients
were slightly higher than those in adults and elderly patients
(Table II).
The majority of patients (n=60; 87.0 %), including all
patients with SID, received Privigen® at a hospital, the doc-
tor’s office, or an infusion center. Six (8.7%) patients received
their treatment at home, and 3 (4.3 %) patients received their
treatment both at home and at a hospital or infusion center.
Effectiveness
Effectiveness was analyzed separately in the main cohort of
patients (n=69) and in infants with SCID (n=3). In the main
cohort, themean±SD of themost recent available trough serum
IgG levels achieved on Privigen® was 970±248 mg/dL (n=63;
median: 954 mg/dL; range: 407–1,581 mg/dL; Table III). Only
two (2.9 %) patients had confirmed trough serum IgG levels of
less than 500 mg/dL, both with SID secondary to cancer. The
mean trough IgG levels on therapy were similar across all age
Table II Dosing and administration of Privigen® and previous IgG treatment
All patients Infants (0–2 y. o.) Children and adolescents
(3–15 y. o.)
Adults (16–64 y. o.) Elderly (>64 y. o.)
Number of patients, n (%) 69 (100.0) 6 (8.7) 17 (24.6) 32 (46.4) 14 (20.3)
Privigen® monthly dose [mg/kg/month],
mean (SD)
532 (250) 481 (137) 606 (230) 522 (307) 483 (133)
Range, min–max 196–2000 360–731 333–1110 196–2000 354–833
Privigen® regimen, n (%)
Q4W 59 (85.5) 4 (5.8) 15 (21.7) 26 (37.7) 14 (20.3)
Q3W 8 (11.6) 2 (2.9) 1 (1.4) 5 (7.2) 0 –
Q2W 2 (2.9) 0 – 1 (1.4) 1 (1.4) 0 –
Average infusion rate [mL/kg/h], mean (SD) 1.46 (0.58) 1.58 (0.54) 1.66 (0.38) 1.43 (0.67) 1.26 (0.49)
IgG-pretreated, n (%) 35 (50.7) 0 – 10 (14.5) 17 (24.6) 8 (11.6)
IVIGa 27 (39.1) 0 – 7 (10.1) 15 (21.7) 5 (7.2)
SCIGa 8 (11.6) 0 – 3 (4.3) 2 (2.9) 3 (4.3)
IgG immunoglobulin G, IVIG intravenous immunoglobulin, n number of patients, QxW every x weeks, SCIG subcutaneous immunoglobulin, SD
standard deviation, y. o. years old
a Patients with >1 previous line of treatment were classified by the last IgG product received before Privigen®
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classes, as well as between the IgG-pretreated and IgG-naïve
patients (Fig. 1). As expected, IgG levels increased in previ-
ously untreated patients (n=27, three patients with substantial
levels of maternal IgG at the start of Privigen® treatment were
excluded from this analysis; data were not available in three
other IgG-naïve patients). The median increase in IgG levels in
these patients was 447 mg/dL (range: 201 mg/dL to 1,014 mg/
dL). However, the change in individual patients was poorly
correlated with the monthly IgG dose (Fig. 2). Similarly, no
consistent change in serum IgG concentrations was seen in
IVIG-pretreated patients (n=23; median change: 165 mg/dL,
range: −784 mg/dL to 936 mg/dL). SCIG-pretreated patients
showed a wide variety of IgG level changes despite almost
unchanged monthly IgG doses (n=8; median change: 84 mg/
dL, range: −350 mg/dL to 542 mg/dL).
Ten (14.5 %) patients had a total of 11 SBIs, resulting in an
annualized SBI rate of 0.087 events/patient/year (upper one-
sided 99 % CI: 0.170; Table III). The most common SBI was
pneumonia (n=8; 11.6%; 0.063 events/patient/year). Other SBIs
observed were bacteremia/sepsis (n=2; 2.9 %) and visceral
abscess (n=1; 1.4 %). Most common other infections were
(rhino-) sinusitis (n=24; 34.8 %) and upper respiratory tract
infection (URI; n=10; 14.5 %). One patient had documented
recurrent URI that was considered one infection. The annualized
SBI rates in pediatric (n=23) and adult/elderly (n=46) patients
were 0.078 events/patient/year and 0.091 events/patient/year,
respectively. The annualized rate of any infection in all patients
was 1.082 events/patient/year (two-sided 95%CI: 0.909–1.279);
in pediatric and adult/elderly patients the rates were 1.215 events/
patient/year and 0.899 events/patient/year, respectively.
Patients spent an average of 3.63 days/patient/year in hospital
due to infection. However, 303 of 460 days were attributed to
two patients with severe disease. An adolescent patient with
CVID was hospitalized for a total of 210 days due to “atypical
pneumonia”, sinusitis and gastroenteritis caused by Salmonella
spp. An adult patient with hypogammaglobulinemia was hospi-
talized for a total of 93 days due to two episodes of SBI (intestinal
abscess and bacteremia caused by Campylobacter spp.). The
annualized rate of hospitalization in the remaining children and
adolescents was 2.85 days/patient/year and in adults 0.59 days/
patient/year. Patients with SCID included into the main cohort
were hospitalized on average for 0.89 days/patient/year. Over
two-thirds of the patient cohort (n=51; 73.9 %) were not hospi-
talized due to infection during Privigen® treatment.
The annualized rate of days missed from performing nor-
mal daily activities due to infection was 4.45 days/patient/
Table III Effectiveness of Privigen® treatment











Number of patients, n (%) 69 (100.0) 6 (8.7) 17 (24.6) 32 (46.4) 14 (20.3) 2 (2.9) 67 (97.1)
Most recent available trough serum IgG
levels, mean (SD)a
970 (248) 856 (188) 960 (211) 1011 (244) 938 (335) 1238 (371) 961 (243)
SBIs, n (number of events) 10 (11) 0 3 (3) 5 (6) 2 (2) 1 (2) 9 (9)
Annualized rate [events/patient/year] 0.087 0 0.112 0.093 0.086 0.392 0.074
Upper one-sided 99 % CI 0.170 0 0.375 0.225 0.363 1.649 0.155
Other infections, n (number of events) 44 (126) 5 (14) 11 (33) 22 (62) 6 (17) 2 (6) 42 (120)
Annualized rate [events/patient/year] 0.995 1.180 1.230 0.957 0.734 1.177 0.988
Two-sided 95 % CI 0.829–1.185 0.645–1.981 0.847–1.729 0.725–1.223 0.428–1.176 0.432–2.562 0.819–1.818
Any infection, n (number of events) 46 (137) 5 (14) 12 (36) 23 (68) 6 (19) 2 (8) 44 (129)
Annualized rate [events/patient/year] 1.082 1.180 1.342 1.050 0.821 1.569 1.062
Two-sided 95 % CI 0.909–1.279 0.645–1.981 0.941–1.859 0.815–1.331 0.494–1.282 0.678–3.092 0.866–1.262
Days in hospital due to infection, n (total days) 18 (460)b 2 (47) 10 (278)b 5 (130)b 1 (5) 2 (303) 16 (157)
Annualized rate [events/patient/year] 3.63b 3.96 10.36b 2.01b 0.22 59.44 1.29
Days missed from performing normal daily
activities due to infection, n (total days)
23 (563)b 2 (63) 10 (316)b 10 (179)b 1 (5) 2 (303) 21 (260)
Annualized rate [events/patient/year] 4.45b 5.31 11.78b 2.76b 0.22 59.44 2.14
Days on antibiotics due to prophylaxis or
infection, n (total days)c
40 (5223) 6 (545) 13 (2577) 16 (1662) 5 (439) 1 (50) 39 (5173)
Annualized rate [events/patient/year] 47.0 45.9 96.1 32.6 20.5 17.1 47.8
CI confidence interval, IgG immunoglobulin G, n number of patients, SBI serious bacterial infection, SD standard deviation, w/o without, y. o. years old
a Data not available in 6 patients (n=63, including 6 infants, 17 children and adolescents, 29 adults and 11 elderly patients)
b Total numbers of events and the annualized rates were strongly influenced by 2 patients with severe disease (a child and an adult)
c Data not available in 7 patients (n=62, including 6 infants, 17 children and adolescents, 27 adults and 12 elderly patients)
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year. This rate was considerably lower upon exclusion of the
patients with severe disease (remaining patients: n=67;
2.14 days/patient/year). Forty (58.0 %) patients were treated
with antibiotics for prophylaxis or treatment of infection,
including 12 (16.7 %) patients who were continuously receiv-
ing antibiotics while on Privigen®. The annualized rate of
antibiotic treatment based on total exposure of all patients to
Privigen® was 47.0 days/patient/year. Antibiotic use was
much more frequent in children and adolescents than in adults
and elderly patients (Table III).
IgG Treatment and Effectiveness in Infant Patients With SCID
Treatment schedules and effectiveness of Privigen® in infants
with SCID (n=3) were analyzed separately. These patients
were started on Privigen® at 2–4 months of age and either did
not undergo HSCT (n=1) or underwent the transplantation
shortly before starting Privigen® (n=2). One patient with two
episodes of gram-negative bacteria sepsis was treated with
1,000 mg/kg Privigen® once weekly, resulting in a monthly
IgG dose of 4,000 mg/kg/month. A second patient had dis-
seminated Pneumocystis jirovecii infection and was treated
with 2,000 mg/kg Privigen® every 3 weeks (2,700 mg/kg/
month). The third patient was treated with 400 mg/kg
Privigen® every 3 weeks (532 mg/kg/month). In spite of the
high monthly doses of Privigen®, trough serum IgG levels in
these patients were similar to the main patient cohort
(Table IV). The patients experienced a total of 6 SBIs, includ-
ing bacteremia/sepsis (n=2), septic arthritis, and pneumonia
(each n=1). Two of these patients were hospitalized for the
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Fig. 1 Trough serum IgG levels achieved with Privigen® by age class
and IgG-pretreatment. IgG-naïve (n=30) and IgG-pretreated (n=32) pa-
tients with available serum IgG levels both before and after the start of
Privigen® were analyzed by age class: infants (0–2 y. o.), children and
adolescents (3–15 y. o.), adults (16–64 y. o.) and elderly patients (>64 y.
o.). The mean values of the most recent available trough serum IgG levels
are shown along with the SD (error bars) and the number of patients in









































Fig. 2 Changes in monthly IgG dose and trough serum IgG levels.
Patients with available serum IgG levels both before and after the switch
to Privigen® were analyzed, including IgG-naïve (n=27; green), IVIG-
pretreated (blue; n=23) and SCIG-pretreated (red; n=8) patients. Three
IgG-naïve infants were excluded from this analysis due to high content of
maternal IgG before the start of the Privigen® treatment. The change in
trough serum IgG levels was plotted against the absolute monthly
Privigen® dose (IgG-naïve patients) or against the change in monthly
IgG dose (IgG-pretreated patients). An IVIG-pretreated patient with the
highest increase of monthly IgG dose received an unusually highmonthly
Privigen® dose (2,000 mg/kg/month) due to a severe form of disease.
Correlation was analyzed by calculating the linear regression coefficients
(R) for IgG-naïve and IgG-pretreated patients (IVIG- and SCIG-
pretreated combined)
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hospitalization rate of 279.3 days/patient/year. The patients
were treated with antibiotics for the whole period of
hospitalization.
Tolerability
The occurrence of AEs was recorded in all patients, including
infants with SCID (n=72). Thirteen (18.1 %) patients experi-
enced at least one AE, including 10 (13.9 %) patients with
AEs possibly related to Privigen®. The most common related
AEs were headache after infusion (n=6; 8.3 %), fever, and
chills or rigors (each n=2; 2.8 %; Table V). One SAE of
swelling of the legs after Privigen® infusion was reported in
an adult patient with IgG subclass deficiency and was consid-
ered not related to Privigen®. No other SAEs were reported
(excluding infections reported under effectiveness). One pa-
tient with SCID died at the age of 6.5 months due to severe
viral infection, before receiving HSCT.
The majority of patients (n=61; 84.7 %) did not have any
non-infectious complications of the underlying disease during
Privigen® treatment. One patient experienced a combination of
transfusion-dependent, steroid-resistant Diamond-Blackfan ane-
mia, iron overload and chronic enteroviral infection. No cases of
Privigen®-related anemia (positive Coombs test), changes in
liver or renal function, or accumulation of proline were reported.
Discussion
This study shows that Privigen® doses and regimens previously
tested in prospective clinical studies were also used in clinical
practice, which allows a valid comparison of the real-life effec-
tiveness and tolerability with the clinical studies results.
The minimal duration of the Privigen® treatment was set
for 3 months, which ensured that the majority of patients were
at steady-state Privigen® dosing at the time of collecting data
for this report. The mean trough IgG levels achieved in this
study and resulting from doses recommended in the respective
Privigen® labels closely matched previously published results
of clinical studies (811–1,027 mg/dL [8, 9]) and other IVIG
products (830–1,120 mg/dL [11, 15–17]). The vast majority
of the patients reached IgG levels above 500 mg/dL, with a
mean trough serum IgG level of 970 mg/dL for the main
cohort. Indeed, higher IgG levels have been shown to be
associated with lower frequencies of infections [18, 19], and
the incidence of pneumonia we observed fell within the 95 %
CI for the corresponding IgG level (0.008–0.068 events/
Table IV Privigen® dosing and
effectiveness in infants with SCID
CI confidence interval, IgG im-
munoglobulin G, n number of
patients, n/a not applicable, SBI
serious bacterial infection, SD
standard deviation
a Data not available in 1 patient
(n=2)
b Upper one-sided 99 % CI
c Two-sided 95 % CI
Mean, range or n Annualized rate
(events/patient/year)
CI
Privigen® monthly dose [mg/kg/month],
mean (SD)
2411 (1752) n/a n/a
Range, min–max 532–4000 n/a n/a
Most recent available trough serum IgG
levels, mean (SD)a
1018 (182) n/a n/a
SBIs, n (number of events) 3 (6) 5.319 12.917b
Other infections, n (number of events) 1 (2) 1.773 0.215–6.404c
Any infection, n (number of events) 3 (8) 7.092 3.062–13.973c
Days in hospital due to infection, n
(total days)
3 (315) 279.2 n/a
Days missed from day care due to
infection, n (total days)
3 (315) 279.2 n/a
Days on antibiotics due to prophylaxis or
infection, n (total days)
3 (315) 279.2 n/a
Table V Tolerability of Privigen® treatment (all patients including in-
fants with SCID)







Any AE 13 18.1 10 13.9
Headache after infusion 6 8.3 6 8.3
Fever 2 2.8 2 2.8
Chills or rigors 2 2.8 2 2.8
Fatigue 1 1.4 1 1.4
Syncope during or after
infusion
1 1.4 1 1.4
Emesis 1 1.4 1 1.4
Increased serum creatinine 1 1.4 1 1.4
Diarrhea 1 1.4 0 0
Neuropathy 1 1.4 0 0
Any SAE 1 1.4 0 0
Swelling of lower limbs
after infusion
1 1.4 0 0
AE adverse event, SAE serious adverse event
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patient/year) in the pooled analysis by Orange et al. [18]. The
median IgG levels were consistent with contemporary guide-
lines that aim to achieve at least 700–800 mg/dL. Observed
variability of individual IgG levels of more than 3.5 fold (407–
1,581 mg/dL) supports the recent findings that ‘protective’
IgG levels are highly individual [19–21]. The annualized SBI
rate observed in this study fell into the range reported in
clinical studies (0.080–0.120 events/patient/year [8, 9]). The
annualized rate of any infection in clinical practice was lower
than in clinical studies (3.55–3.79 events/patient/year [8, 9]),
which may be partially attributed to the retrospective
nature of this study, where some episodes of mild infec-
tions might not have been recorded, unlike clinical trials
in which symptoms are entered into diaries every day.
Another possible factor was the inclusion of patients with
IgG subclass deficiency, with or without antibody produc-
tion, that are commonly excluded from clinical trials. The
annualized rate of hospitalization was above the range deter-
mined in clinical studies (0.33–2.31 days/patient/year [8, 9]).
This result was caused by the presence of two patients with
severe disease in the cohort. Such patients have been previously
reported and may have been excluded from clinical studies or
analyzed separately [12]. The rest of the patients demonstrated
hospitalization rates within the clinical study range. Despite the
higher hospitalization rate, the annualized rate of days missed
from performing normal daily activities was lower than in the
clinical studies (7.94–8.97 days/patient/year [8, 9]), but these
data may have been underestimated due to the retrospective
nature of the study.
We observed high variability in the IgG levels achieved
with Privigen® treatment in different IgG-naïve patients,
which was poorly correlated with the monthly IgG dose but
consistent with the observations of Lucas et al. [20] on the
variability of doses required to achieve desired IgG levels in
different patients. Switching from a previous IgG product to
Privigen® resulted in a similar variety of IgG level changes.
These findings are in line with a recent analysis that demon-
strated high variability of the relationship between IgG levels
and IgG dose in individual patients with PID [22]. In addition,
the present study included patients whose immunoglobulin
levels could be expected to be variable over time (such as
patients with multiple myeloma), and interventions that may
have influenced serum IgG levels, such as bone marrow
transplantation or HSCT, were not prohibited. This study also
included patients who switched from SCIG to IVIG
(Privigen®), from Privigen® to SCIG and from other IVIG
products to Privigen®. Thus, our observations highlight the
importance of individualized choice of treatment and the
necessity of targeting a certain clinical response (e.g., level
of protection against infections), rather than predefined serum
IgG levels, when selecting the dosing regimen. The target of
treatment may also change over time, depending on the pa-
tient’s preference and clinical condition.
Age class analysis showed high similarity of Privigen®
doses and effectiveness between all age groups, with the
exception of more frequent hospitalization and antibiotic
use in pediatric patients than in adult and elderly patients.
These results are consistent with the similarity of results
obtained in clinical studies with pediatric and adult patients
[5, 8, 9].
Unlike registration clinical studies, this study also included
patients with SID. These patients were treated with identical
doses of Privigen® administered at a hospital or infusion
center. Remarkably, inclusion of patients with SID did not
prevent the results of this study from matching those of
clinical studies, suggesting similar effectiveness and tolerabil-
ity of Privigen® in SID and PID in clinical practice. One
limitation of this result is that all patients with SID were
treated at the same clinical site. Nevertheless, the tolerability
observed in our study was very similar to the results of another
single-center study in patients with SID [23].
We analyzed the dosage and effectiveness of Privigen®
in infants with SCID separately from the main patient
cohort due to potential differences in their disease mech-
anisms. Patients with SCID before and shortly after HSCT
may lack cell-mediated immunity, a defect that cannot be
rescued by replacement IgG therapy. This is one of the
reasons why such patients are usually not included in
clinical studies of IgG products. Indeed, these patients
demonstrated a distinct treatment and outcome pattern:
two of these patients received exceptionally high monthly
IgG doses of 2,700–4,000 mg/kg/month, and all three
were hospitalized and treated with antibiotics for extended
periods of time.
Privigen® was well tolerated in clinical practice. The ab-
sence of Privigen®-related SAEs and the percentage of
infusion-related AEs, with headache being the most common
related AE, matched the results of recent clinical studies with
Privigen® (18 % [8, 9]) and other IVIG products (14 % to
20 % [11, 15–17]).
Conclusions
This study demonstrates that the effectiveness and tolerability
of Privigen® previously observed in clinical studies are also
evident in clinical practice in Europe and the US, in both adult
and pediatric patients. Few exceptions in Privigen® dosage
and effectiveness were observed in infant patients with SCID
and patients with severe disease.
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